Date Title Description PDF
08 May 2024 On P&L The Company releases the press release related to the first three months of 2024 financial results Download
08 May 2024 On P&L The Company releases the first three months 2024 financial results presentation Download
25 Apr 2024 On business and financial situation ROVI announces agreement to manufacture pre-filled syringes Download
27 Feb 2024 On P&L The Company releases the press release related to the full year 2023 financial results. Download
27 Feb 2024 On P&L The Company releases the full year 2023 financial results presentation. Download

Pages

Date Title Description PDF
22 Nov 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 November 2021 and 19 November 2021 Download
16 Nov 2021 Liquidity and counterparty agreements The Company informs of the termination of the Liquidity Agreement Download
16 Nov 2021 On business and financial situation The Company releases the presentation related to its strategy update because of its 2021 Capital Markets Day Download
15 Nov 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 5 November 2021 and 12 November 2021 Download
05 Nov 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted on 3 and 4 November Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages